CombinatoRx, Incorporated (NASDAQ: CRXX) up 8% to $3.45 on no recent developments. The 52-week range is $3.11 to $7.37. Yesterday, the company hit a 52-week low so perhaps it had nowhere to go but up.
Corcept Therapeutics Inc. (NASDAQ: CORT) up 11% today. Despite several statistically insignificant Phase III clinical trials of lead drug, a psychotic depression treatment, Corlox, the company initiated further trials in December. Friday the company entered into an agreement with Kingsbridge Capital Limited to purchase up to $60 million in new shares to finance their trials. Shares are trading at $3.60 off a 52-week range of $1.10 to $6.85.
Omrix Biopharmaceuticals, Inc. (OMRI) is still rising from an analyst assertion Monday that the biosurgery franchise unit with Johnson and Johnson leads its industry. Since Monday, shares have spiked from $13.32 to $16.04, a 20% increase. Today, shares are up 8%. The 52-week range is $11.81 to $39.07.
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) granted orphan-status to MELAS syndrome drug treatment, resveratrol. The designation gives Sirtris 7 years of marketing exclusivity upon FDA approval. Shares down $0.73 to $13.12 on heavy trading volume. The 52-week range of $9.50 to $21.99.
April 2, 2008